ÂÜÀòÂÒÂ×

Dr. Stebbing is Professor and Faculty of Medicine at Imperial College London, Department of Surgery and Cancer. He specializes in treating advanced malignancy. Dr. Stebbing is a Fellow of the Royal College of Physicians and the Royal College of Pathologists, sits on the advisory Boards of a number of international cancer committees, and has over 600 peer-reviewed publications in journals such as Lancet, New England Journal, and the Journal of Clinical Oncology.

He uses a number of new biomarker-based approaches, with an emphasis on circulating tumor cells and cell free DNA. His laboratory work is concentrated on new druggable target discovery, genomics and gene regulation examining the role of non-coding RNAs in stem cells.

Dr. Stebbing holds MD and PhD from University of Oxford and Imperial College and performed his residency at Johns Hopkins University. During the COVID-19 pandemic he originally identified dual mechanisms for baricitinib’s use and led international efforts leading to its FDA approval.